Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study [0.03%]
西格列汀与奥美拉唑、法莫替丁或氢氧化镁/铝及吗丁啉联用在健康受试者中的药代动力学相互作用研究：一项开放标签、随机、自身对照试验
Song Ren,David W Boulton
Song Ren
Saxagliptin is an orally administered, highly potent, and selective dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. This study was conducted to determine the effect of magnesium and aluminum hydroxides plus ...
Randomized Controlled Trial
Clinical pharmacology in drug development. 2019 May;8(4):549-558. DOI:10.1002/cpdd.634 2019
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial [0.03%]
心肌梗死后的左室功能障碍患者中，缓激肽抑制剂fulacimstat的安全性和耐受性——CHIARA MIA 1试验结果
Hans-Dirk Düngen,Lars Kober,Savina Nodari et al.
Hans-Dirk Düngen et al.
The chymase inhibitor fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). The aim of the ...
Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults [0.03%]
中国健康成人单次和多次服用氟替卡松福莫特鲁/乌美溴铵的药代动力学特征研究
Yan Li,Huafang Li,Yucheng Sheng et al.
Yan Li et al.
The pharmacokinetics (PK) and safety of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) after single and repeat dosing in healthy Chinese adults were assessed. In this open-label study (NCT02837380), subjects receive...
Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin [0.03%]
食物对艾托格列净及其复方制剂疗效的影响：艾托格列净/沙格列汀和艾托格列净/二甲双胍联用
Vaishali Sahasrabudhe,Daryl J Fediuk,Kyle Matschke et al.
Vaishali Sahasrabudhe et al.
Ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, is approved in the United States and European Union for the treatment of type 2 diabetes in adults, both as monotherapy and as part of fixed-dose combination (FDC) therapies wit...
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects [0.03%]
一项在健康志愿者中的随机、双盲、安慰剂对照、剂量递增评估司来吉尤单抗硫酸盐（soluble guanylate cyclase，sGC）刺激剂praliciguat的安全性、耐受性、药代动力学和药效学的多剂量研究
John P Hanrahan,James D Wakefield,Phebe J Wilson et al.
John P Hanrahan et al.
Nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling is central to the regulation of several physiological processes, including blood flow and inflammation. Deficient NO signaling is implicated i...
An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults [0.03%]
艾美恩韦在健康成年男性体内的开放性、单次给药人体动态平衡研究
Kota Kato,Martin den Adel,Dorien Groenendaal-van de Meent et al.
Kota Kato et al.
Amenamevir is an inhibitor of the helicase-primase enzyme complex developed for the treatment of varicella zoster virus. This mass balance study investigated the absorption, metabolism, and excretion of a single dose (200 mg) of 14 C-labele...
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability [0.03%]
每日一次单片复方达芦那韦、考比司他、恩曲他滨和替诺福韦阿尔芬酰胺与联合服用各单独药物的生物等效性及食物对生物利用度的影响
Herta M Crauwels,Bryan Baugh,Erika Van Landuyt et al.
Herta M Crauwels et al.
The effect of food on the bioavailability of the components of the once-daily, single-tablet human immunodeficiency virus (HIV) type 1 regimen containing darunavir (DRV 800 mg), cobicistat (COBI 150 mg), emtricitabine (FTC 200 mg), and teno...
Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects [0.03%]
含罗贝戈利钠/盐酸二甲双胍的复方固定剂量片（CKD-395 0.5/1000 mg）与单药联合给药在中国健康男性受试者中的药代动力学特征：随机、双盲、双模拟、两制剂、4周期交叉试验及含餐对CKD-395代谢的影响
Sun-Young Kim,Ji-Young Jeon,Shin Jung Park et al.
Sun-Young Kim et al.
This study aimed to compare the pharmacokinetic profile of combined CKD-395 0.5/1000 mg treatment with that of the coadministration of lobeglitazone sulfate 0.5 mg and metformin hydrochloride (HCl) extended-release (XR) 1000 mg and assess t...
Randomized Controlled Trial
Clinical pharmacology in drug development. 2019 Jul;8(5):576-584. DOI:10.1002/cpdd.625 2019
Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4-Way Replicate Crossover Investigation by a Reference-Scaled Average Bioequivalence Approach [0.03%]
在中国受试者中餐前和餐后服用沙普格雷丁的生物等效性：采用参考标准平均生物等效性方法的四周期交叉试验
Y H Ding,B Liu,J F Lou et al.
Y H Ding et al.
Sarpogrelate is widely used to treat peripheral vascular disorders. However, it has been demonstrated to have a poor pharmacokinetic (PK) profile and marked within-subject variability. Here, the bioequivalence of 2 formulations of sarpogrel...
Randomized Controlled Trial
Clinical pharmacology in drug development. 2019 Aug;8(6):713-720. DOI:10.1002/cpdd.624 2019
Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects [0.03%]
健康日本受试者中恩曲他滨/特诺福韦阿拉芬酰胺复方制剂的药物代谢动力学：与恩曲他滨/特诺福韦分散片相比
Hiroyuki Yamada,Takuma Yonemura,Takanori Nemoto et al.
Hiroyuki Yamada et al.
A fixed-dose combination of tenofovir alafenamide (TAF) and emtricitabine (FTC) is available in 2 tablet strengths in Japan (FTC/TAF 200/10 mg and FTC/TAF 200/25 mg). These are used once daily in combination with other antiretroviral agents...